EN DE
Watch Anti-Microbial Savior BioteQ Co., Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Anti-Microbial Savior BioteQ Co., Ltd. (6864) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Anti-Microbial Savior BioteQ Co., Ltd. stock TWD 10.42, price TWD 33.95, that is 69.3% below the price, quality 31 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006864002

AM Anti-Microbial Savior BioteQ Co., Ltd. logo Thin data Nov 9, 2026

Anti-Microbial Savior BioteQ Co., Ltd.

6864 · TWO
Weakest Setup

Our calculation puts a fair price 69% below what the stock costs today.

Low debt
Fair value 10.42 TWD · Strongly overvalued
Quality 31/100
Weak Growth (revenue 3y −36.0 %/yr in TWD)
Negative free cash flow
Trails peers (2/7)
Narrow moat 3/100 · thin data
Thin data
⚠ Dilution
Watch Anti-Microbial Savior BioteQ Co., Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

86.30 TWD 33.95 TWD Fair Value 10.42 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

11‑month range 33.95 TWD – 86.30 TWD · fair‑value band 6.88 TWD – 13.03 TWD · the 33.95 TWD price screens above the 10.42 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Anti-Microbial Savior BioteQ Co. in your weekly email

Every Wednesday you see whether Anti-Microbial Savior BioteQ Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Anti-Microbial Savior BioteQ Co., Ltd. focuses on the research and development of pharmaceutical drug products in Taiwan. It develops technology patenting of medical fungi. The company also provides MEDIACE, an antibacterial Ingredient containing skin-friendly materials and medicinal fungal extracts.

Show moreShow less

In addition, it provides customized functional face masks. The company was founded in 2018 and is headquartered in Kaohsiung, Taiwan.

Stock analysis

Anti-Microbial Savior BioteQ Co., Ltd. (6864) currently trades at 33.95 TWD, while our model-based Fair Value estimate is 10.42 TWD, 69% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 6.88 TWD (bear) to 13.03 TWD (bull), the price of 33.95 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Anti-Microbial Savior BioteQ Co., Ltd. reported revenue of 706K TWD in FY2025 versus 88.0K TWD in FY2021, a compound +68.3%/yr. Reported net income was −93.6M TWD in FY2025.

Key figures

Market cap 1.7B TWD (≈ $51.9M) Micro · EPS (TTM) −2.58 TWD · Return on equity −25.0% · Return on assets (EBIT) −26.5% (5-year average) · Operating margin −5,270% · Revenue (TTM) 1.3M TWD · Revenue growth (YoY) +190% · Free cash flow −84.6M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 61% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −69%, 6864 screens richer than that median.

Fair Value models

Bear 6.88 TWD Fair Value 10.42 TWD Bull 13.03 TWD
Price 33.95 TWD · Downside -69.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 8.09 TWD 12.26 TWD 15.33 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 8.09 TWD 12.26 TWD 15.33 TWD 54

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 64
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+15.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−36.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−32,164.8% (2021) → −13,595.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6864 screens overvalued: fair value 69% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Anti-Microbial Savior BioteQ Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −69.3% · Below median
Profitability
Return on assets −18.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 190.3% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.34× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6864
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6864
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6864
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6864
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6864
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6864
argenx SE ARGX $927.21 $908.40 −2% vs 6864
CSL Limited CSL A$200.77 A$183.04 −9% vs 6864
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6864
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6864

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Anti-Microbial Savior BioteQ Co., Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Anti-Microbial Savior BioteQ Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6864

Frequently asked questions

Is Anti-Microbial Savior BioteQ Co., Ltd. (6864) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 10.42 TWD versus a price of 33.95 TWD, about 69% lower (overvalued).
What is the fair value of 6864?
Our model-based fair value for Anti-Microbial Savior BioteQ Co., Ltd. is 10.42 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 33.95 TWD.
What is the quality score of 6864?
Anti-Microbial Savior BioteQ Co., Ltd. has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Our model-based price target is the fair value of 10.42 TWD (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 6.88 TWD, optimistic scenario 13.03 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Anti-Microbial Savior BioteQ Co., Ltd. stock forecast for 2026?
Our models put fair value at 10.42 TWD, about 69% lower versus a price of 33.95 TWD (overvalued). Cautious scenario 6.88 TWD, optimistic scenario 13.03 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Anti-Microbial Savior BioteQ Co., Ltd. reported trailing-twelve-month revenue of about 1.3M TWD (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anti-Microbial Savior BioteQ Co., Ltd. it is 10.42 TWD per share (as of Nov 9, 2026), against a price of 33.95 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Anti-Microbial Savior BioteQ Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6864 trades above its calculated fair value: price 33.95 TWD, fair value 10.42 TWD, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6864?
No. The price is what the market pays today (33.95 TWD); the fair value is what the company's own numbers justify (10.42 TWD). For Anti-Microbial Savior BioteQ Co., Ltd. the two are 23.53 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Anti-Microbial Savior BioteQ Co., Ltd. worth?
The market values Anti-Microbial Savior BioteQ Co., Ltd. at about 1.7B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 33.95 TWD; our models calculate a fair value of 10.42 TWD per share.
What do the bullish and bearish scenarios say about 6864?
Our models span a range for Anti-Microbial Savior BioteQ Co., Ltd.: cautious scenario 6.88 TWD, base 10.42 TWD, optimistic 13.03 TWD per share (as of Nov 9, 2026, price 33.95 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Balance-sheet figures for Anti-Microbial Savior BioteQ Co., Ltd. (as of Nov 9, 2026): return on equity −25.0%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 6864 from its 52-week high?
Anti-Microbial Savior BioteQ Co., Ltd. trades at 33.95 TWD, about 61% below its 52-week high of 86.30 TWD and at the low of 33.95 TWD (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 10.42 TWD is for.
Which stocks are comparable to Anti-Microbial Savior BioteQ Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anti-Microbial Savior BioteQ Co., Ltd. stock attractive at the current price?
The data as of Nov 9, 2026: price 33.95 TWD, calculated fair value 10.42 TWD (−69%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6864 calculated?
We run Anti-Microbial Savior BioteQ Co., Ltd. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 10.42 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Anti-Microbial Savior BioteQ Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The closing price on Nov 6, 2026 was 33.95 TWD. Our model-based fair value is 10.42 TWD, about 69% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anti-Microbial Savior BioteQ Co., Ltd. right now?
The price sits above even our optimistic bull case (13.03 TWD). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (6.88 TWD to 13.03 TWD) leaves room in how you read the outcome.

Key figures of Anti-Microbial Savior BioteQ Co., Ltd.

How large is the market capitalisation of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The market capitalisation of Anti-Microbial Savior BioteQ Co., Ltd. is 1.7B TWD (≈ $51.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Earnings per share at Anti-Microbial Savior BioteQ Co., Ltd. are −2.58 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The return on equity (ROE) of Anti-Microbial Savior BioteQ Co., Ltd. is −25.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
On an EBIT basis the return on assets of Anti-Microbial Savior BioteQ Co., Ltd. is −26.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
The operating margin of Anti-Microbial Savior BioteQ Co., Ltd. is −5,270% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anti-Microbial Savior BioteQ Co., Ltd. (6864)?
Revenue at Anti-Microbial Savior BioteQ Co., Ltd. is growing +190% versus a year earlier (3y avg −36.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Anti-Microbial Savior BioteQ Co., Ltd. (6864) generate?
The free cash flow of Anti-Microbial Savior BioteQ Co., Ltd. is −84.6M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Anti-Microbial Savior BioteQ Co., Ltd. in the live analysis

One click puts Anti-Microbial Savior BioteQ Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.